News from sosei heptares A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 19, 2019, 03:00 ET Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives

Sosei Group Corporation ("the Company"; TSE: 4565) announces the formation of a new Scientific Advisory Board (SAB) to advise on the Company's...


Nov 12, 2019, 03:00 ET Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine...


Oct 09, 2019, 03:00 ET Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target

Sosei Group Corporation ("the Company"; TSE: 4565) announces that it has been notified by its partner Genentech, a member of the Roche Group, of its...


Oct 01, 2019, 03:00 ET Sosei Heptares Notes the Announcement of Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma

Sosei Group Corporation ("the Company"; TSE: 4565) notes that Novartis has announced positive results from its Phase III IRIDIUM trial. The results...


Sep 12, 2019, 04:00 ET Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum

Sosei Group Corporation ("the Company"; TSE: 4565) today held an Investor R&D Event in Tokyo, Japan, discussing how the integration of its...


Aug 13, 2019, 03:33 ET Sosei Heptares Operational Highlights and Consolidated Results for the First Half of FY2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...


Aug 05, 2019, 02:30 ET Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership

Sosei Group Corporation ("the Company") (TSE: 4565) announces that it has entered into a strategic multi-target partnership with Takeda...


Jul 18, 2019, 02:34 ET Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals

Sosei Group Corporation ("the Company"; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has received approval from the US Food...


Jul 16, 2019, 02:30 ET Sosei Heptares Enters Into Multi-target Research Collaboration and License Agreement With Genentech

Sosei Group Corporation ("the Company") (TSE: 4565) announces that it has entered into a multi-target research collaboration and license agreement...


Jun 10, 2019, 03:00 ET Sosei Heptares to Receive New $3 Million Milestone Payment from Pfizer, as It Advances a Second Candidate from the GPCR Collaboration for Clinical Development

Sosei Group Corporation ("the Company"); (TSE: 4565) and its strategic alliance partner Pfizer announce that a new clinical candidate from their...


May 23, 2019, 19:46 ET Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency

Sosei Group Corporation ("the Company"; TSE: 4565) announces it has been notified today by its strategic alliance partner Novartis (SWX: NOVN) that...


May 22, 2019, 09:55 ET Sosei Heptares Notes New Positive Phase II Data for QVM149, a Potential Novel Inhaled Combination for Treating Asthma, Were Presented at ATS 2019

Sosei Group Corporation ("the Company"; TSE: 4565) notes that its partner Novartis presented key Phase II data for QVM149, a potential new inhaled...


May 14, 2019, 03:37 ET Sosei Heptares Reports Progress With Pfizer as Multi-target Collaboration Delivers First Candidate for Clinical Advancement

Sosei Group Corporation ("the Company"); (TSE: 4565) reports encouraging progress and initial success of its strategic multi-target drug discovery...


Mar 21, 2019, 19:50 ET Sosei Heptares Announces that Ultibro® Breezhaler® and Seebri® Breezhaler® Launched in China for the Treatment of COPD

Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro® Breezhaler® and Seebri® Breezhaler® have been launched by Novartis in China ...


Feb 20, 2019, 01:52 ET Sosei Heptares Starts New Clinical Development Program

Sosei Group Corporation ("the Company"; TSE: 4565), announces that the first healthy subject has been dosed with a novel small molecule HTL0030310 in ...


Feb 04, 2019, 02:41 ET Sosei Heptares Announces Medicxi to Invest Up To €40 Million in New Collaboration Based on its Orexin Agonist Program

Sosei Group Corporation ("the Company") (TSE: 4565), announces it has entered into a structured financing agreement[1] with Medicxi, a venture fund...


Jan 31, 2019, 01:36 ET Sosei Heptares to Launch ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis in Japan

Sosei Group Corporation ("the Company"; TSE: 4565), announces its wholly-owned Japanese subsidiary Sosei Co., Ltd. ("the Business"), will launch...


Jan 07, 2019, 02:07 ET Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2

Milestone achieved with next generation immuno-oncology candidate AZD4635, a novel adenosine 2A receptor antagonist Sosei Group Corporation ("the...


Dec 13, 2018, 02:00 ET Sosei Heptares Starts New Clinical Development Program - First Subject Dosed in Phase I Study of HTL0014242, a Selective mGlu5 Negative Allosteric Modulator in Development to Treat Psychiatric and Neurological Disorders

Sosei Group Corporation ("the Company"; TSE: 4565), announces that the first healthy subject has been dosed with a novel small molecule HTL0014242 in ...


Dec 12, 2018, 01:42 ET Sosei Group Corporation Announces Changes in Executive Management team - Shinichi Tamura Appointed as Chairman, President & Chief Executive Officer

Tamura is the founder and former CEO and brings more than 40 years of experience in the pharmaceutical industry Sosei Group Corporation ("the...